Login to Your Account

Aslan readies pivotal study of varlitinib for biliary tract cancer

By Carmen Ho
Staff Writer

Friday, April 28, 2017

HONG KONG – Aslan Pharmaceuticals Pte Ltd., an oncology-focused biotech, is set to commence a global pivotal study to treat biliary tract cancer with its lead product, varlitinib, after getting clearance from the FDA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription